View ValuationBiostax 将来の成長Future 基準チェック /06現在、 Biostaxの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 21Biostax Corp. Intends to Voluntary Delist Common Stock from OTC Pink MarketplaceOn February 19, 2025, Biostax Corp. (the "Company") notified the Securities and Exchange Commission (the "SEC") of the Company's intention to voluntarily file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934). The Company intends to file the Form 25 with the SEC on or about February 26, 2025 to effect the voluntary delisting of the Company's common stock from the OTC Pink marketplace and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This decision to voluntarily delist and deregister was made by the Company's Board of Directors after careful consideration of the advantages and disadvantages of being a public reporting company. The Company is eligible to deregister its common stock as its assets are substantially below $10 million. As of November 20, 2024, the Company's total assets were approximately $6.669,000 million. The Board has determined that the costs and expenses associated with being a public reporting company outweigh the benefits to the Company and its stockholders at this time. It is important to note that this action is entirely voluntary and was not requested or demanded by any regulatory body or exchange. The Company anticipates that its obligation to file periodic reports and other information with the SEC will be suspended upon the effective date of Form 25. The Company intends to file a Form 15 with the SEC on or about February 26, 2025, to suspend its duty to file reports under Sections 13 and 15(d) of the Exchange Act.お知らせ • Aug 15Biostax Corp. announced delayed 10-Q filingOn 08/14/2024, Biostax Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Biostax Corp. announced delayed 10-Q filingOn 05/15/2024, Biostax Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Biostax Corp. announced delayed annual 10-K filingOn 04/01/2024, Biostax Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Biostax Corp. Appoints Craig Suro as a DirectorBiostax Corp. announced the appointment of Influential Business Leader Roger “Craig” Suro as Director. Renowned Virginia native, Mr. Suro, has emerged as a driving force in the realms of business innovation, public policy, and community revitalization. With an extensive background in business development and public service, Mr. Suro has continually spearheaded transformative initiatives that have left a lasting impact on Virginia's economic landscape. Mr. Suro's journey began as Virginia’s Assistant Secretary of Health and Human Resources under the office of Secretary Jane Woods where he exhibited exceptional leadership in policy coordination, legislative affairs, and relationship building with state healthcare agencies. His expertise in healthcare policies laid the foundation for his venture into the private sector, where he co-founded Caretime LLC in 2010. This private healthcare software company, under Mr. Suro's guidance, achieved remarkable success, experiencing an average annual revenue growth of 52%. Recognized for his entrepreneurial acumen, Mr. Suro ventured into the aquaculture industry in 2014, founding the not-for profit, Tangier Island Oyster Company. His vision revitalized the economy of Tangier Island, providing over 1 million premium brand oysters annually to select restaurants creating a range of new employment opportunities and establishing a sustainable market for premium oysters. In recent years, Mr. Suro's focus has shifted towards the burgeoning field of Biotechnology. Collaborating with leading companies in the Richmond/Petersburg region, he has been instrumental in driving innovative drug research and manufacturing projects. His consultancy work ensures that these initiatives maximize growth, fostering synergies that benefit communities, national safety, and public health. Mr. Suro's dedication to community development is reflected in his service on several boards and committees. He serves on the Greater Richmond YMCA Board and currently volunteers on the Property and Facilities committee. Presently, he serves on the HCA Central Division Region Market Advisory Committee, the Community Board for Blue Ridge Bank, and the Board of Trustees for The Steward School. With a legacy marked by innovation, collaboration, and community empowerment, Craig Suro continues to shape Virginia's future. His dynamic approach and visionary leadership make him a driving force behind transformative change, leaving an indelible mark on businesses, communities, and industries alike.お知らせ • Nov 03Biostax Corp. Appoints Mary Clay Caperton to its Board of DirectorsBiostax Corp. announced the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys &Girls Clubs of Richmond, St. Marys Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond. In her remarkable career, Ms. Caperton has demonstrated exceptional prowess as a fundraising professional, showcasing an unwavering passion for aiding not-for-profit organizations in realizing their missions. With an impressive track record, she has adeptly secured substantial financial contributions and cultivated robust donor networks. She has taken on pivotal roles, serving on and chairing various committees such as the Organizations Development or Advancement Committee, the Capital Campaign Committee, and the Governance and Executive Committee. Her expertise has shined through as she has successfully assumed the role of Tournament Director for numerous Charity Golf Events, Banquets, and Auctions. Early in her career, Ms. Caperton served as the Assistant Marketing Manager for the Richmond Braves, the AAA Franchise of the Atlanta Braves. Subsequently, at Sports Development League (SDL), she honed her resourcefulness, flexibility, and adeptness in dealing with diverse personalities. These invaluable skills laid the foundation for her future roles in event management. Mrs. Capertons impact extended to the academic sphere as well. Collaborating with Virginia Commonwealth University, she played a pivotal role in the development of a Sports Marketing Graduate Program, overseeing internships, and contributing to the formulation of event management and operations curricula. Furthermore, her outstanding reputation led to her appointment as the Director of the Henrico County Open on the Nationwide Tour by The PGA Tour. Over six years, she adeptly managed this televised event, showcasing her unwavering dedication to excellence and organizational prowess. Mrs. Capertons multifaceted career stands as a testament to her unwavering commitment to excellence, innovation, and impactful contributions to both the sports and not-for-profit sectors.お知らせ • Aug 17Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and AihImmune Therapeutics, Inc. d/b/a Biostax Corp. announced that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-122 and the U.S. Food and Drug Administration (FDA) has finalized those transfers. The INDs that were transferred to Biostax include IND 146955 for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis, IND 147347 for the treatment of Nonalcoholic Liver Disease (NAFLD) and IND 127303 for the treatment of Autoimmune Hepatitis along with the Orphan Designation for Autoimmune Hepatitis. These INDs were transferred from TaiwanJ Pharmaceuticals, who licensed the development and commercialization of JKB-122 to Biostax Corp. in 2022. JKB-122 is a small molecule and a long-acting TLR4 antagonist that has been shown to play a prominent role in the pathogenesis of certain autoimmune and inflammatory conditions including the treatments of chronic liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD), Autoimmune Hepatitis (AIH), and Non-Alcoholic Steatohepatitis (Nash).お知らせ • Jan 04Immune Therapeutics, Inc. Announces Director ResignationsImmune Therapeutics, Inc. announced that on December 15, 2022, Kevin Phelps, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Mr. Phelps resigned from his position as a director of the Company, effective December 31, 2022. Mr. Phelps’ resignation was not the result of any material dispute or disagreement with the Company, the Company’s management, or the Company’s Board on any matter relating to the operations, policies or practices of the Company. On December 17, 2022, Dr. Roscoe Moore, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Dr. Moore resigned from his position with the Company, effective on December 31, 2022. Dr. Moore’s resignation was not the result of any material dispute or disagreement with the Company, the Company’s management, or the Company’s Board on any matter relating to the operations, policies, or practices of the Company.お知らせ • Nov 11+ 1 more updateImmune Therapeutics, Inc. Announces Executive ChangesImmune Therapeutics, Inc. announced that its President, and Director, Stephen Wilson, PhD, resigned from his positions with Immune on November 3, 2022, citing a lack of Director and Officer insurance. In addition, Dr. Clifford Selsky resigned from his position as a Director of Immune on November 4, 2022. Dr. Selsky’s resignation was not the result of any material dispute or disagreement with Immune, Immune’s management, or Immune’s board of directors on any matter relating to the operations, policies, or practices of Immune. For the remainder of this year, Kelly O. Wilson, the current Chief Operating Officer, will fill the role of Interim President. Ms. Wilson, age 52, has served as the Chief Operating Officer of the Company since August 2022. From 2013 to April 2020, Ms. Wilson was the Company’s Chief Technology Officer. From September 2014 to April 2020, Ms. Wilson also served as the Chief Technology and Information Officer of Cytocom Inc., a clinical-stage biopharmaceutical company and former subsidiary of the Company. From August 2016 to August 2019, Ms. Wilson was the Director of Program and Project Management of Cytocom from April 2020-April 2022; during that time Cytocom merged with Cleveland Biolabs Inc. and became Statera Biopharma Inc. From May 2022 to July 2022, Ms. Wilson was the Chief Operating Officer of Biostax, Inc., an immunotherapy startup. Ms. Wilson graduated with honors from the University of Central Florida with a master’s degree in systems design and a bachelor’s degree in English.お知らせ • Sep 28Immune Therapeutics, Inc. Appoints H. Louis Salomonksy to Its Board of DirectorsImmune Therapeutics, Inc. announced the appointment of Louis Salomonsky to the Company's Board of Directors. Mr. SalomonskyLouis Salomonsky is a real estate professional with decades of experience designing, developing, and managing commercial real estate. Mr. Salomonsky's firm, Historic Housing LLC, has expertise in the adaptive reuse of historic buildings, as well as the construction of new buildings for multi-family residential. Mr. Salomonsky works in two dynamic property markets, namely Richmond, Virginia and Washington, DC, creating assets collectively valued by Mr. Salomonsky's firm at $750 million, over the past 28 years. Mr. Salomonsky's firm specializes in federal Low-Income Housing Tax Credits and historic rehabilitation tax credits, and conventionally financed three to twelve-story market rate new-construction buildings.Mr. Salomonsky has a long track record of community and professional volunteerism including serving on task forces examining historic tax credit legislation for the Commonwealth of Virginia and the government structure of the City of Richmond. Mr. Salomonsky has served as the Vice Rector and as a Member of the Board of Visitors for Virginia State University. He currently serves on the UVA School of Architecture Foundation Board.お知らせ • Sep 01Immune Therapeutics, Inc. announced a financing transactionImmune Therapeutics, Inc. announced that it will receive $5,000,000 in funding on August 31, 2022. The company will issue non-convertible debt in the transaction. The minimum investment accepted from any outside investor is $25,000. The company will issue securities pursuant to exemption provided under Regulation D.お知らせ • Aug 10Immune Therapeutics, Inc. announced delayed 10-Q filingOn 08/09/2022, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 05+ 1 more updateImmune Therapeutics, Inc. Announces the Appointment of Kelly O’Brien Wilson as Chief Operating OfficerImmune Therapeutics, Inc. announced the appointment of Kelly O’Brien Wilson, age 51, as Chief Operating Officer filling the previously vacant position. In that role, Ms. Wilson will be responsible for overseeing the company’s core business units and subsidiaries and for working directly with the Company’s international leadership, assisting with country management organization and functions. She will work to maximize the potential of the Company’s growing portfolio of products, many of which are in a combination of approved and growth phases. Ms. Wilson brings over 25 years of leadership, technology, and operational experience to Immune. She has held senior management and development roles with both startups and large corporations in the private, public, and government sectors across multiple industries including biotechnology, manufacturing, and computer software. She was the Chief Technology Officer and Director of Human Resources at Immune from 2015-2020 and has experience managing many different business departments including information technology, human resources, and corporate operations. Ms. Wilson graduated with honors from the University of Central Florida with a master’s degree in systems design and a bachelor’s degree in English.お知らせ • Aug 03Immune Therapeutics, Inc. announced that it has received $0.4 million in fundingOn August 2, 2022, Immune Therapeutics, Inc. closed the transaction. The transaction included participation from single investor.お知らせ • Jul 24+ 1 more updateImmune Therapeutics, Inc. Announces Executive ChangesImmune Therapeutics, Inc. announced the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors. Dr. Wilson brings over 20 years of experience in biomedical research, executive management, and corporate governance. He is a trained immunologist. In addition, he is, among other things, an Associate Clinical Professor at the University of California, San Diego, and he previously served as the Chief Operating Officer at the La Jolla Institute for Immunology as it grew to become an international powerhouse. Immune also announced that Kevin Phelps has stepped down from his positions as the company’s CFO, President, and CEO, but he will remain a member of Immune’s Board of Directors. The appointment of Dr. Wilson as Immune’s CEO, President, and interim CFO is expected to further strengthen IMUN’s global executive leadership team to drive its next phase of growth and operational success within a new operational model, initially focused on regulatory approval and commercialization of existing assets that treat patients with inflammatory disease.お知らせ • Jul 23Immune Therapeutics, Inc. Announces Chief Executive Officer ChangesImmune Therapeutics, Inc. announced the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors. Dr. Wilson brings over 20 years of experience in biomedical research, executive management, and corporate governance. He is a trained immunologist. In addition, he is, among other things, an Associate Clinical Professor at the University of California, San Diego, and he previously served as the Chief Operating Officer at the La Jolla Institute for Immunology as it grew to become an international powerhouse. Immune also announced that Kevin Phelps has stepped down from his positions as the company’s CFO, President, and CEO, but he will remain a member of Immune’s Board of Directors. The appointment of Dr. Wilson as Immune’s CEO, President, and interim CFO is expected to further strengthen IMUN’s global executive leadership team to drive its next phase of growth and operational success within a new operational model, initially focused on regulatory approval and commercialization of existing assets that treat patients with inflammatory disease.お知らせ • Jun 04Immune Therapeutics, Inc. Announces Board ChangesImmune Therapeutics, Inc. announced that it will expand its Board of Directors from two to five members. Joining the Board effective May 31, 2022 will be Dr. Stephen Wilson, Dr. Clifford Selsky, and Mr. Robert Wilson who were appointed for interim terms until such time as an annual meeting of shareholders can be organized to provide a formal vote on the candidates. Dr. Stephen Wilson. Dr. Wilson is a trained immunologist with more than 25 years of experience in biomedical research and executive management. He is the Chief Innovation Officer of Statera Biopharma, Inc. and an Associate Clinical Professor at the University of California, San Diego. Prior, he served as Chief Operating Officer at the La Jolla Institute for Immunology; during his tenure the Institute grew from $14M in annual R&D to become a global leader in immunology research with nearly $1B in total operations as well as ranked #1 place to work in the world by The Scientist magazine. His original research has been published in high impact journals, and he has served as principal or co-principal investigator on more than $75M in competitive grants and awards, most recently developing the 2021 X-Prize winning rapid CoVID-19 diagnostic test. Dr. Wilson has served as an advisor to elite medical research organizations, served on national boards and is a founding scientist and board member of Invivoscribe Technologies, Inc., a leading molecular diagnostics and oncology therapeutics company. Dr. Wilson earned his doctorate from the University of Arizona’s College of Medicine in Immunology, and was a fellow of the National Multiple Sclerosis Society and National Institutes of Health. Dr. Selsky has been a practicing pediatrician in Central Florida for the past twenty years. He is the founder of the Children’s Center for Cancer and Blood Disease at Florida Hospital cancer institute, which he established after training in pediatrics at Yale New Haven hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine. Dr. Selsky is board certified in Pediatrics, Pediatric hematology and oncology and Palliative medicine. Currently, he is a pediatrician at Family First Pediatrics which he established in 2013. Also, an accomplished scientist, Dr. Selsky obtained his PH.D. in Microbiology and Molecular Genetics at the University of Miami School of Medicine. He then did DNA repair research studies at the radiobiology laboratory at Harvard School of Public Health and the biophysics laboratory at Stanford University. Mr. Wilson has spent more than 25 years building and launching companies. As a business strategist, retail marketer and content developer, Robert is experienced is assessing business situations, conducting research, creating strategic plans, recommending solutions to management, monitoring competitors, and measuring the results of marketing strategies. Robert has been involved in securing more than $150 million in early round and angel funding, developing launch and pivot strategies, and identifying growth opportunities for more than two dozen public companies ranging from the energy sector and electric vehicles to healthcare and lifestyle brands.お知らせ • May 19Immune Therapeutics, Inc. announced delayed 10-Q filingOn 05/18/2021, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Immune Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2021, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 28Immune Therapeutics, Inc. Announces the Resignation of Michael Sander as a DirectorOn January 21, 2021, Michael Sander notified the Board of Directors of Immune Therapeutics, Inc. of his resignation as a director of the Company, effective on January 21, 2021, to pursue other interests. Mr. Sander served as director from November 2019. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Biostax は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:BTAX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2024N/A-200N/A6/30/2024N/A-200N/A3/31/2024N/A-200N/A12/31/2023N/A-200N/A9/30/2023N/A-2-10N/A6/30/2023N/A-4-1-1N/A3/31/2023N/A-1-1-1N/A12/31/2022N/A-4-1-1N/A9/30/2022N/A-3-1-1N/A6/30/2022N/A2-1-1N/A3/31/2022N/A000N/A12/31/2021N/A400N/A9/30/2021N/A300N/A6/30/2021N/A400N/A3/31/2021N/A300N/A12/31/2020N/A200N/A9/30/2020N/A200N/A6/30/2020N/A-300N/A3/31/2020N/A-300N/A12/31/2019N/A-300N/A9/30/20190-300N/A6/30/20190-500N/A3/31/20190-8-1-1N/A12/31/20180-8-1-1N/A9/30/20180-11-1-1N/A6/30/20180-10N/A-2N/A3/31/20180-5N/A-2N/A12/31/2017N/A-7N/A-2N/A9/30/2017N/A-9N/A-2N/A6/30/2017N/A-11N/A-3N/A3/31/2017N/A-15N/A-3N/A12/31/20160-20N/A-3N/A9/30/20160-20N/A-3N/A6/30/20160-20N/A-3N/A3/31/20160-18N/A-3N/A12/31/20150-14N/A-3N/A9/30/20150-22N/A-3N/A6/30/20150-29N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BTAXの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BTAXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BTAXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BTAXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BTAXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BTAXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 23:37終値2026/05/18 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biostax Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 21Biostax Corp. Intends to Voluntary Delist Common Stock from OTC Pink MarketplaceOn February 19, 2025, Biostax Corp. (the "Company") notified the Securities and Exchange Commission (the "SEC") of the Company's intention to voluntarily file a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934). The Company intends to file the Form 25 with the SEC on or about February 26, 2025 to effect the voluntary delisting of the Company's common stock from the OTC Pink marketplace and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This decision to voluntarily delist and deregister was made by the Company's Board of Directors after careful consideration of the advantages and disadvantages of being a public reporting company. The Company is eligible to deregister its common stock as its assets are substantially below $10 million. As of November 20, 2024, the Company's total assets were approximately $6.669,000 million. The Board has determined that the costs and expenses associated with being a public reporting company outweigh the benefits to the Company and its stockholders at this time. It is important to note that this action is entirely voluntary and was not requested or demanded by any regulatory body or exchange. The Company anticipates that its obligation to file periodic reports and other information with the SEC will be suspended upon the effective date of Form 25. The Company intends to file a Form 15 with the SEC on or about February 26, 2025, to suspend its duty to file reports under Sections 13 and 15(d) of the Exchange Act.
お知らせ • Aug 15Biostax Corp. announced delayed 10-Q filingOn 08/14/2024, Biostax Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Biostax Corp. announced delayed 10-Q filingOn 05/15/2024, Biostax Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Biostax Corp. announced delayed annual 10-K filingOn 04/01/2024, Biostax Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Biostax Corp. Appoints Craig Suro as a DirectorBiostax Corp. announced the appointment of Influential Business Leader Roger “Craig” Suro as Director. Renowned Virginia native, Mr. Suro, has emerged as a driving force in the realms of business innovation, public policy, and community revitalization. With an extensive background in business development and public service, Mr. Suro has continually spearheaded transformative initiatives that have left a lasting impact on Virginia's economic landscape. Mr. Suro's journey began as Virginia’s Assistant Secretary of Health and Human Resources under the office of Secretary Jane Woods where he exhibited exceptional leadership in policy coordination, legislative affairs, and relationship building with state healthcare agencies. His expertise in healthcare policies laid the foundation for his venture into the private sector, where he co-founded Caretime LLC in 2010. This private healthcare software company, under Mr. Suro's guidance, achieved remarkable success, experiencing an average annual revenue growth of 52%. Recognized for his entrepreneurial acumen, Mr. Suro ventured into the aquaculture industry in 2014, founding the not-for profit, Tangier Island Oyster Company. His vision revitalized the economy of Tangier Island, providing over 1 million premium brand oysters annually to select restaurants creating a range of new employment opportunities and establishing a sustainable market for premium oysters. In recent years, Mr. Suro's focus has shifted towards the burgeoning field of Biotechnology. Collaborating with leading companies in the Richmond/Petersburg region, he has been instrumental in driving innovative drug research and manufacturing projects. His consultancy work ensures that these initiatives maximize growth, fostering synergies that benefit communities, national safety, and public health. Mr. Suro's dedication to community development is reflected in his service on several boards and committees. He serves on the Greater Richmond YMCA Board and currently volunteers on the Property and Facilities committee. Presently, he serves on the HCA Central Division Region Market Advisory Committee, the Community Board for Blue Ridge Bank, and the Board of Trustees for The Steward School. With a legacy marked by innovation, collaboration, and community empowerment, Craig Suro continues to shape Virginia's future. His dynamic approach and visionary leadership make him a driving force behind transformative change, leaving an indelible mark on businesses, communities, and industries alike.
お知らせ • Nov 03Biostax Corp. Appoints Mary Clay Caperton to its Board of DirectorsBiostax Corp. announced the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys &Girls Clubs of Richmond, St. Marys Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond. In her remarkable career, Ms. Caperton has demonstrated exceptional prowess as a fundraising professional, showcasing an unwavering passion for aiding not-for-profit organizations in realizing their missions. With an impressive track record, she has adeptly secured substantial financial contributions and cultivated robust donor networks. She has taken on pivotal roles, serving on and chairing various committees such as the Organizations Development or Advancement Committee, the Capital Campaign Committee, and the Governance and Executive Committee. Her expertise has shined through as she has successfully assumed the role of Tournament Director for numerous Charity Golf Events, Banquets, and Auctions. Early in her career, Ms. Caperton served as the Assistant Marketing Manager for the Richmond Braves, the AAA Franchise of the Atlanta Braves. Subsequently, at Sports Development League (SDL), she honed her resourcefulness, flexibility, and adeptness in dealing with diverse personalities. These invaluable skills laid the foundation for her future roles in event management. Mrs. Capertons impact extended to the academic sphere as well. Collaborating with Virginia Commonwealth University, she played a pivotal role in the development of a Sports Marketing Graduate Program, overseeing internships, and contributing to the formulation of event management and operations curricula. Furthermore, her outstanding reputation led to her appointment as the Director of the Henrico County Open on the Nationwide Tour by The PGA Tour. Over six years, she adeptly managed this televised event, showcasing her unwavering dedication to excellence and organizational prowess. Mrs. Capertons multifaceted career stands as a testament to her unwavering commitment to excellence, innovation, and impactful contributions to both the sports and not-for-profit sectors.
お知らせ • Aug 17Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and AihImmune Therapeutics, Inc. d/b/a Biostax Corp. announced that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-122 and the U.S. Food and Drug Administration (FDA) has finalized those transfers. The INDs that were transferred to Biostax include IND 146955 for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis, IND 147347 for the treatment of Nonalcoholic Liver Disease (NAFLD) and IND 127303 for the treatment of Autoimmune Hepatitis along with the Orphan Designation for Autoimmune Hepatitis. These INDs were transferred from TaiwanJ Pharmaceuticals, who licensed the development and commercialization of JKB-122 to Biostax Corp. in 2022. JKB-122 is a small molecule and a long-acting TLR4 antagonist that has been shown to play a prominent role in the pathogenesis of certain autoimmune and inflammatory conditions including the treatments of chronic liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD), Autoimmune Hepatitis (AIH), and Non-Alcoholic Steatohepatitis (Nash).
お知らせ • Jan 04Immune Therapeutics, Inc. Announces Director ResignationsImmune Therapeutics, Inc. announced that on December 15, 2022, Kevin Phelps, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Mr. Phelps resigned from his position as a director of the Company, effective December 31, 2022. Mr. Phelps’ resignation was not the result of any material dispute or disagreement with the Company, the Company’s management, or the Company’s Board on any matter relating to the operations, policies or practices of the Company. On December 17, 2022, Dr. Roscoe Moore, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Dr. Moore resigned from his position with the Company, effective on December 31, 2022. Dr. Moore’s resignation was not the result of any material dispute or disagreement with the Company, the Company’s management, or the Company’s Board on any matter relating to the operations, policies, or practices of the Company.
お知らせ • Nov 11+ 1 more updateImmune Therapeutics, Inc. Announces Executive ChangesImmune Therapeutics, Inc. announced that its President, and Director, Stephen Wilson, PhD, resigned from his positions with Immune on November 3, 2022, citing a lack of Director and Officer insurance. In addition, Dr. Clifford Selsky resigned from his position as a Director of Immune on November 4, 2022. Dr. Selsky’s resignation was not the result of any material dispute or disagreement with Immune, Immune’s management, or Immune’s board of directors on any matter relating to the operations, policies, or practices of Immune. For the remainder of this year, Kelly O. Wilson, the current Chief Operating Officer, will fill the role of Interim President. Ms. Wilson, age 52, has served as the Chief Operating Officer of the Company since August 2022. From 2013 to April 2020, Ms. Wilson was the Company’s Chief Technology Officer. From September 2014 to April 2020, Ms. Wilson also served as the Chief Technology and Information Officer of Cytocom Inc., a clinical-stage biopharmaceutical company and former subsidiary of the Company. From August 2016 to August 2019, Ms. Wilson was the Director of Program and Project Management of Cytocom from April 2020-April 2022; during that time Cytocom merged with Cleveland Biolabs Inc. and became Statera Biopharma Inc. From May 2022 to July 2022, Ms. Wilson was the Chief Operating Officer of Biostax, Inc., an immunotherapy startup. Ms. Wilson graduated with honors from the University of Central Florida with a master’s degree in systems design and a bachelor’s degree in English.
お知らせ • Sep 28Immune Therapeutics, Inc. Appoints H. Louis Salomonksy to Its Board of DirectorsImmune Therapeutics, Inc. announced the appointment of Louis Salomonsky to the Company's Board of Directors. Mr. SalomonskyLouis Salomonsky is a real estate professional with decades of experience designing, developing, and managing commercial real estate. Mr. Salomonsky's firm, Historic Housing LLC, has expertise in the adaptive reuse of historic buildings, as well as the construction of new buildings for multi-family residential. Mr. Salomonsky works in two dynamic property markets, namely Richmond, Virginia and Washington, DC, creating assets collectively valued by Mr. Salomonsky's firm at $750 million, over the past 28 years. Mr. Salomonsky's firm specializes in federal Low-Income Housing Tax Credits and historic rehabilitation tax credits, and conventionally financed three to twelve-story market rate new-construction buildings.Mr. Salomonsky has a long track record of community and professional volunteerism including serving on task forces examining historic tax credit legislation for the Commonwealth of Virginia and the government structure of the City of Richmond. Mr. Salomonsky has served as the Vice Rector and as a Member of the Board of Visitors for Virginia State University. He currently serves on the UVA School of Architecture Foundation Board.
お知らせ • Sep 01Immune Therapeutics, Inc. announced a financing transactionImmune Therapeutics, Inc. announced that it will receive $5,000,000 in funding on August 31, 2022. The company will issue non-convertible debt in the transaction. The minimum investment accepted from any outside investor is $25,000. The company will issue securities pursuant to exemption provided under Regulation D.
お知らせ • Aug 10Immune Therapeutics, Inc. announced delayed 10-Q filingOn 08/09/2022, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 05+ 1 more updateImmune Therapeutics, Inc. Announces the Appointment of Kelly O’Brien Wilson as Chief Operating OfficerImmune Therapeutics, Inc. announced the appointment of Kelly O’Brien Wilson, age 51, as Chief Operating Officer filling the previously vacant position. In that role, Ms. Wilson will be responsible for overseeing the company’s core business units and subsidiaries and for working directly with the Company’s international leadership, assisting with country management organization and functions. She will work to maximize the potential of the Company’s growing portfolio of products, many of which are in a combination of approved and growth phases. Ms. Wilson brings over 25 years of leadership, technology, and operational experience to Immune. She has held senior management and development roles with both startups and large corporations in the private, public, and government sectors across multiple industries including biotechnology, manufacturing, and computer software. She was the Chief Technology Officer and Director of Human Resources at Immune from 2015-2020 and has experience managing many different business departments including information technology, human resources, and corporate operations. Ms. Wilson graduated with honors from the University of Central Florida with a master’s degree in systems design and a bachelor’s degree in English.
お知らせ • Aug 03Immune Therapeutics, Inc. announced that it has received $0.4 million in fundingOn August 2, 2022, Immune Therapeutics, Inc. closed the transaction. The transaction included participation from single investor.
お知らせ • Jul 24+ 1 more updateImmune Therapeutics, Inc. Announces Executive ChangesImmune Therapeutics, Inc. announced the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors. Dr. Wilson brings over 20 years of experience in biomedical research, executive management, and corporate governance. He is a trained immunologist. In addition, he is, among other things, an Associate Clinical Professor at the University of California, San Diego, and he previously served as the Chief Operating Officer at the La Jolla Institute for Immunology as it grew to become an international powerhouse. Immune also announced that Kevin Phelps has stepped down from his positions as the company’s CFO, President, and CEO, but he will remain a member of Immune’s Board of Directors. The appointment of Dr. Wilson as Immune’s CEO, President, and interim CFO is expected to further strengthen IMUN’s global executive leadership team to drive its next phase of growth and operational success within a new operational model, initially focused on regulatory approval and commercialization of existing assets that treat patients with inflammatory disease.
お知らせ • Jul 23Immune Therapeutics, Inc. Announces Chief Executive Officer ChangesImmune Therapeutics, Inc. announced the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors. Dr. Wilson brings over 20 years of experience in biomedical research, executive management, and corporate governance. He is a trained immunologist. In addition, he is, among other things, an Associate Clinical Professor at the University of California, San Diego, and he previously served as the Chief Operating Officer at the La Jolla Institute for Immunology as it grew to become an international powerhouse. Immune also announced that Kevin Phelps has stepped down from his positions as the company’s CFO, President, and CEO, but he will remain a member of Immune’s Board of Directors. The appointment of Dr. Wilson as Immune’s CEO, President, and interim CFO is expected to further strengthen IMUN’s global executive leadership team to drive its next phase of growth and operational success within a new operational model, initially focused on regulatory approval and commercialization of existing assets that treat patients with inflammatory disease.
お知らせ • Jun 04Immune Therapeutics, Inc. Announces Board ChangesImmune Therapeutics, Inc. announced that it will expand its Board of Directors from two to five members. Joining the Board effective May 31, 2022 will be Dr. Stephen Wilson, Dr. Clifford Selsky, and Mr. Robert Wilson who were appointed for interim terms until such time as an annual meeting of shareholders can be organized to provide a formal vote on the candidates. Dr. Stephen Wilson. Dr. Wilson is a trained immunologist with more than 25 years of experience in biomedical research and executive management. He is the Chief Innovation Officer of Statera Biopharma, Inc. and an Associate Clinical Professor at the University of California, San Diego. Prior, he served as Chief Operating Officer at the La Jolla Institute for Immunology; during his tenure the Institute grew from $14M in annual R&D to become a global leader in immunology research with nearly $1B in total operations as well as ranked #1 place to work in the world by The Scientist magazine. His original research has been published in high impact journals, and he has served as principal or co-principal investigator on more than $75M in competitive grants and awards, most recently developing the 2021 X-Prize winning rapid CoVID-19 diagnostic test. Dr. Wilson has served as an advisor to elite medical research organizations, served on national boards and is a founding scientist and board member of Invivoscribe Technologies, Inc., a leading molecular diagnostics and oncology therapeutics company. Dr. Wilson earned his doctorate from the University of Arizona’s College of Medicine in Immunology, and was a fellow of the National Multiple Sclerosis Society and National Institutes of Health. Dr. Selsky has been a practicing pediatrician in Central Florida for the past twenty years. He is the founder of the Children’s Center for Cancer and Blood Disease at Florida Hospital cancer institute, which he established after training in pediatrics at Yale New Haven hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine. Dr. Selsky is board certified in Pediatrics, Pediatric hematology and oncology and Palliative medicine. Currently, he is a pediatrician at Family First Pediatrics which he established in 2013. Also, an accomplished scientist, Dr. Selsky obtained his PH.D. in Microbiology and Molecular Genetics at the University of Miami School of Medicine. He then did DNA repair research studies at the radiobiology laboratory at Harvard School of Public Health and the biophysics laboratory at Stanford University. Mr. Wilson has spent more than 25 years building and launching companies. As a business strategist, retail marketer and content developer, Robert is experienced is assessing business situations, conducting research, creating strategic plans, recommending solutions to management, monitoring competitors, and measuring the results of marketing strategies. Robert has been involved in securing more than $150 million in early round and angel funding, developing launch and pivot strategies, and identifying growth opportunities for more than two dozen public companies ranging from the energy sector and electric vehicles to healthcare and lifestyle brands.
お知らせ • May 19Immune Therapeutics, Inc. announced delayed 10-Q filingOn 05/18/2021, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Immune Therapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2021, Immune Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 28Immune Therapeutics, Inc. Announces the Resignation of Michael Sander as a DirectorOn January 21, 2021, Michael Sander notified the Board of Directors of Immune Therapeutics, Inc. of his resignation as a director of the Company, effective on January 21, 2021, to pursue other interests. Mr. Sander served as director from November 2019.